Latanoprost is a prostaglandin analog (PGA) used to treat glaucoma and ocular hypertension. PGAs are highly effective in lowering intraocular pressure (IOP) with minimal systemic side effects, making them a first-line treatment. However, they can cause mild local side effects, such as transient conjunctival hyperemia, iris pigmentation changes, and eyelash hypertrichosis. In rare cases, due to their pro-inflammatory properties, PGAs have been linked to choroidal detachments, cystoid macular edema, and uveitis reactivation [1].

We report a case of asymmetrical bilateral choroidal detachment associated with latanoprost use.

We present the case of a 53-year-old female with a medical history of hypertension (treated with amlodipine), high myopia (–6.00 D OD, –8.00 D OS), and bilateral pseudophakia (OS: extracapsular cataract extraction; OD: phacoemulsification). She was recently diagnosed with primary open-angle glaucoma (POAG) and initiated on latanoprost 0.005% once daily as monotherapy for less than two weeks. (Initial intraocular pressure before treatment was: 27 mmHg OD and 25 mmHg OG, with normal CCT 520 μm OD

Choroidal detachment (CD) is a rare but recognized adverse effect of prostaglandin analogs (PGAs), including latanoprost, particularly in eyes with predisposing factors such as high myopia and prior intraocular surgery. The exact pathophysiological mechanism remains poorly understood [2]. CD results from the accumulation of fluid in the suprachoroidal space, which is normally kept virtual due to adhesions between the uvea and sclera and a hydrostatic pressure gradient that promotes transscleral

This case underscores the risk of prostaglandin analog-induced severe ocular hypotony, leading to choroidal detachment and hyphema, particularly in eyes with high myopia and prior intraocular surgery. Given the increasing use of PGAs as first-line glaucoma therapy, clinicians should remain vigilant for this rare but vision-threatening complication, especially in predisposed individuals.

The authors declare that they have no competing interest.

There are more references available in the full text version of this article.

© 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.